Quarterly Report

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

For the quarterly period ended October 2, 2005

or

For the transition period from                      to                     

Commission File Number 000-26137

drugstore.com, inc.

(Exact name of registrant as specified in its charter)

411 108 ^th Avenue NE, Suite 1400, Bellevue, Washington 98004

(Address of principal executive offices including zip code)

(425) 372-3200

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   x     No   ¨ .

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act). Yes   x     No   ¨ .

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes   ¨     No   x .

As of November 1, 2005, the registrant had 92,834,823 shares of common stock outstanding.

Table of Contents

DRUGSTORE.COM, INC.

FORM 10-Q

For the three and nine months ended October 2, 2005

INDEX

Table of Contents

PART I—FINANCIAL INFORMATION

DRUGSTORE.COM, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except share and per share data)

(unaudited)

See accompanying notes to condensed consolidated financial statements.

2

Table of Contents

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

See accompanying notes to condensed consolidated financial statements.

3

Table of Contents

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

See accompanying notes to condensed consolidated financial statements.

4

Table of Contents

DRUGSTORE.COM, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

drugstore.com, inc. is a leading online provider of health, beauty, vision and pharmacy solutions. We sell health, beauty, wellness, personal care, sexual well-being, and pharmacy products through our website at www.drugstore.com and prestige beauty products through www.beauty.com , which is also accessible through the drugstore.com website. We offer customized nutritional supplement programs through our wholly owned subsidiary, Custom Nutrition Services, Inc. (CNS), through websites located at www.DrWeilVitaminAdvisor.com , www.zoneprofiler.com , www.pritikin@home.com , and marketplaces located at www.drweil.com and other Dr. Weil-related websites. We sell contact lenses through our wholly owned subsidiary International Vision Direct Corp. and its subsidiaries (collectively, Vision Direct), through websites located at www.visiondirect.com , www.lensmart.com and www.lensquest.com . Our customers are located primarily in the United States and Canada, but our products are available to consumers worldwide.

All customer orders are processed through our websites or via telephone through our toll-free telephone numbers, 1-800-DRUGSTORE and 1-800-VISIONDIRECT. We operate two distribution centers, one approximately 290,000 square foot facility that provides fulfillment capabilities for all of our pharmaceutical and non-pharmaceutical orders delivered by mail, and another approximately 17,000 square foot facility that fulfills our vision orders delivered by mail. Under the terms of an agreement with Rite Aid Corporation (Rite Aid), customers are also able to order existing drugstore.com and Rite Aid refill prescriptions for pickup at any Rite Aid store.

The accompanying condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (GAAP) and the rules and regulations of the Securities and Exchange Commission (SEC). These condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the SEC for interim financial reporting. These condensed consolidated financial statements are unaudited and, in our opinion, include all adjustments, consisting of normal recurring adjustments and accruals, necessary for a fair presentation of the condensed consolidated balance sheets, statements of operating results, and statements of cash flows for the periods presented. Operating results for the periods presented are not necessarily indicative of the results that may be expected for the fiscal year ending January 1, 2006 or any other interim period due to seasonal and other factors. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been omitted in accordance with the rules and regulations of the SEC. The balance sheet at January 2, 2005 has been derived from audited financial statements at that date but does not include all disclosures required by GAAP for complete financial statements. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and accompanying notes included in our annual report on Form 10-K for the fiscal year ended January 2, 2005.

We operate using a 52/53-week retail calendar year, with each of the fiscal quarters in a 52-week fiscal year representing a 13-week period. Fiscal year 2005 is a 52-week year and fiscal year 2004 was a 53-week year, with the fourth quarter of 2004 representing a 14-week period.

The accompanying condensed consolidated financial statements include those of drugstore.com, inc. and our subsidiaries. All material intercompany transactions and balances have been eliminated.

Estimates and Assumptions

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities, revenues and expenses, and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates, and these estimates could be material.

5

Table of Contents

Recent Accounting Pronouncements

Share-Based Payments

On December 16, 2004, the Financial Accounting Standards Board (FASB) issued Statement of Financial Accounting Standards (SFAS) No. 123 (revised 2004), Share-Based Payment (FAS 123R) , which is a revision of SFAS No. 123, Accounting for Stock-Based Compensation (FAS 123). FAS 123R supersedes Accounting Principles Board (APB) Opinion No. 25, Accounting for Stock Issued to Employees (APB 25), and amends SFAS No. 95, Statement of Cash Flows . FAS 123R applies to all stock-based compensation transactions in which a company acquires services by (a) issuing its stock or other equity instruments, except through arrangements resulting from employee stock-ownership plans, or (b) incurring liabilities that are based on the company’s stock price. FAS 123R requires all share-based payments to employees, including grants of employee stock options, to be recognized as an expense in a company’s financial statements based on their fair values at the date of grant. On March 29, 2005, the SEC issued Staff Accounting Bulletin (SAB) No. 107, Share-Based Payments , which expresses the SEC’s views on FAS 123R, including but not limited to applying share-based payments to non-employees, valuation methods, classification of compensation expense and accounting for income tax effects. FAS 123R is effective for public companies no later than the beginning of the fiscal year beginning after June 15, 2005, and we will adopt it in the first quarter of our fiscal year ending December 31, 2006. FAS 123R permits public companies to adopt its requirements using either the modified-prospective method or the modified-retrospective method. We plan to adopt FAS 123R using the modified-prospective method.

As permitted by FAS 123, we currently account for share-based payments to employees using the intrinsic value method under APB 25. As a result, we recognize no compensation expense for employee stock options, except for options granted with an exercise price lower than the market price on the date of grant. The adoption of FAS 123R’s fair value method will require us to recognize compensation expense for employee stock options and other share-based payments to employees, based on their fair market value on the date of grant. This will have a significant impact on our results of operations, although it will have no impact on our overall financial position. The magnitude of the impact of the adoption of FAS 123R cannot be predicted at this time because it will depend on levels of share-based payments granted in the future. However, had we adopted FAS 123R in prior periods, the impact of that standard would have approximated the impact of FAS 123 as described in the disclosure of adjusted net loss and loss per share set forth in Note 5 of our condensed consolidated financial statements ( Stock-Based Compensation ), included in this quarterly report.

Accounting Changes and Error Corrections

In May 2005, the FASB issued SFAS No. 154, Accounting Changes and Error Corrections (SFAS 154), which is a replacement of APB Opinion No. 20, Accounting Changes (APB 20), and SFAS No. 3, Reporting Accounting Changes in Interim Financial Statements . SFAS 154 applies to all voluntary changes in accounting principle and changes the accounting for and reporting of a change in accounting principle. SFAS 154 requires retrospective application to prior periods’ financial statements of a voluntary change in accounting principle unless it is impracticable. APB 20 previously required that most voluntary changes in accounting principle be recognized by including in net income of the period of the change the cumulative effect of changing to the new accounting principle. SFAS 154 requires that a change in method of depreciation, amortization, or depletion for long-lived, non-financial assets be accounted for as a change in accounting estimate that is affected by a change in accounting principle. APB 20 previously required that such a change be reported as a change in accounting principle. SFAS 154 is effective for accounting changes and corrections of errors made in fiscal years beginning after December 15, 2005. We believe the adoption of SFAS 154 will not have a material effect on our financial statements.

Reclassifications

Certain amounts included in the condensed consolidated statement of cash flows for the nine months ended September 26, 2004 have been reclassified to conform to the 2005 presentation. Reclassifications were made between cash, cash equivalents and marketable securities and purchase and sale activity related to marketable securities. Reclassifications include a decrease to purchases of marketable securities of $5.4 million and a decrease to sales of marketable securities of $14.5 million, resulting in a decrease to net cash provided by investing activities of $9.1 million. The reclassifications did not impact our results of operations or financial position.

Net loss per share is computed using the weighted average number of shares of common stock outstanding less the number of shares that are contingently issuable pursuant to contractual terms. Shares associated with stock options and warrants are not included in the calculation of diluted net loss per share as they are antidilutive.

6

Table of Contents

The following table sets forth the computation of basic and diluted net loss per share for the periods indicated:

At October 2, 2005 and September 26, 2004, there were 16,092,273 shares and 12,960,470 shares, respectively, of common stock subject to stock options and 615,000 shares and 500,000 shares, respectively, of common stock subject to warrants that were excluded from the computation of diluted net loss per share as their effect was antidilutive. If we had reported net income, the calculation of these per share amounts would have included the dilutive effect of these common stock equivalents using the treasury stock method.

We account for our employee stock option plan and our employee stock purchase plan using the intrinsic value method, which follows the recognition and measurement principles of APB 25 and related Interpretations. The intrinsic value method of accounting results in stock compensation expense to the extent option exercise prices are set below market prices on the date of grant or when the options are modified. Under APB 25, no compensation expense is recognized when the exercise price of employee stock options equals the fair value of the underlying stock on the date of grant. Deferred stock-based compensation expense is recorded for those situations where the exercise price of an option was lower than the fair value for financial reporting purposes of the underlying common stock on the date of grant. Deferred stock-based compensation expense is being amortized over the vesting period of the underlying options using the multiple-option approach.

For the three-month periods ended October 2, 2005 and September 26, 2004, we recognized stock-based compensation expense of $295,000 and $56,000, respectively, related to the amortization of deferred stock-based compensation related to stock options issued with an exercise price lower than the fair value of the underlying common stock; and $83,000 and $0, respectively, related to the issuance of options and warrants to non-employees for the performance of services. For the nine-month periods ended October 2, 2005 and September 26, 2004, we recognized stock-based compensation expense of $1,186,000 and $219,000, respectively, related to the amortization of deferred stock-based compensation related to stock options issued with an exercise price lower than the fair value of the underlying common stock; $145,000 and $400,000, respectively, related to certain options that were modified for terminated employees; and $300,000 and $0, respectively, related to the issuance of options and warrants to non-employees for the performance of services. For the nine-month periods ended October 2, 2005 and September 26, 2004, we reversed $0 and $4,000, respectively, of stock-based compensation expense as a result of employee terminations.

FAS 123, which was amended by SFAS No. 148, Accounting for Stock-Based Compensation — Transition and Disclosure , requires companies that continue to follow APB 25 to provide disclosures of the impact of applying the fair value method of FAS 123. We account for stock issued to non-employees in accordance with the provisions of FAS 123 and Emerging Issue Task Force (EITF) Issue No. 96-18, Accounting for Equity Instruments That Are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services.

7

Table of Contents

If the stock-based compensation granted to employees under our stock option plan and employee stock purchase plan had been determined based on the fair value method, as promulgated by FAS 123, our net loss would have been adjusted to the following amounts for the three- and nine-month periods ended October 2, 2005 and September 26, 2004:

The fair value of each option grant is estimated on the date of grant using the Black-Scholes option-pricing model, assuming no expected dividends. The following weighted average assumptions were utilized in arriving at the fair value of each option grant:

On February 14, 2005, in connection with the performance of executive recruiting services, we issued to Heidrick & Struggles, Inc. a warrant to purchase 115,000 shares of our common stock at $2.36 per share. This warrant expires in February 2008.

On March 2, 2005, we issued 10.0 million shares of our common stock to Ziff Asset Management, L.P. (Ziff) in a private placement, for cash consideration of $26.0 million. Pursuant to the terms of the stock purchase agreement, Ziff agreed that it will not, directly or indirectly, sell, transfer or otherwise dispose of any of the common stock purchased for a period of one year, and we agreed to prepare and file a registration statement with the SEC for the resale of all the common shares within nine months from the consummation of the sale. We expect to use the proceeds received, net of issuance costs of $39,000 and estimated future registration costs, for general corporate purposes, including, but not limited to, investments in marketing initiatives and technology infrastructure enhancements.

Legal Proceedings

Class Action Laddering Litigation . On and after July 6, 2001, eight stockholder class action lawsuits were filed in the United States District Court for the Southern District of New York naming drugstore.com as a defendant, along with the underwriters and certain of our present and former officers and directors (the Individual Defendants), in connection with our July 27, 1999 initial public offering and March 15, 2000 secondary offering (together, the Offerings). The complaints against drugstore.com have been consolidated into a single action and a Consolidated Amended Complaint, which is now the operative complaint, was filed on April 19, 2002. The suit purports to be a class action filed on behalf of purchasers of our common stock during the period July 28, 1999 to December 6, 2000. In general, the complaint alleges that the prospectuses through which we conducted the Offerings were materially

8

Table of Contents

false and misleading for failure to disclose, among other things, that (i) the underwriters of the Offerings allegedly had solicited and received excessive and undisclosed commissions from certain investors in exchange for which the underwriters allocated to those investors material portions of the restricted number of shares issued in connection with the Offerings and (ii) the underwriters allegedly entered into agreements with customers whereby the underwriters agreed to allocate drugstore.com shares to customers in the Offerings in exchange for which customers agreed to purchase additional drugstore.com shares in the after-market at predetermined prices. The complaint asserts violations of various sections of the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended. The action seeks damages in an unspecified amount and other relief. The action is being coordinated with approximately 300 other nearly identical actions filed against other companies or their former officers and directors. On July 15, 2002, we moved to dismiss all claims against us and the Individual Defendants. On October 9, 2002, the Court dismissed the Individual Defendants from the case without prejudice based on stipulations of dismissal filed by the plaintiffs and the Individual Defendants. On February 19, 2003, the Court denied the motion to dismiss the complaint against drugstore.com. On October 13, 2004, the Court certified a class in nine of the approximately 300 other nearly identical actions and noted that the decision is intended to provide strong guidance to all parties regarding class certification in the remaining cases. Plaintiffs have not yet moved to certify a class in our case.

We have approved a settlement agreement and related agreements, which set forth the terms of a settlement between drugstore.com, the plaintiff class and the vast majority of the other issuer defendants or, in the case of bankrupt issuers, their directors and officers. Among other provisions, the settlement agreement provides for a release of drugstore.com and the Individual Defendants for the conduct alleged in the action to be wrongful. We would agree to undertake certain responsibilities, including agreeing to assign away, not assert, or release certain potential claims we may have against our underwriters. The settlement agreement also provides a guaranteed recovery of $1 billion to the plaintiffs for the cases relating to all of the approximately 300 issuers. To the extent that the underwriter defendants settle all of the cases for at least $1 billion, no payment will be required under the issuers’ settlement agreement. To the extent that the underwriter defendants settle for less than $1 billion, the issuers are required to make up the difference. We anticipate that any potential financial obligation of drugstore.com to the plaintiffs pursuant to the terms of the settlement agreement and related agreements will be covered by existing insurance, and we have already satisfied our deductible. We are currently not aware of any material limitations from our insurance carriers on the expected recovery of any potential financial obligation to the plaintiffs. Our carriers are solvent and we are not aware of any uncertainties as to the legal sufficiency of an insurance claim with respect to any recovery by the plaintiffs. Therefore, we do not expect that the settlement will involve any payment by us. If material limitations on the expected recovery of any potential financial obligation to the plaintiffs from drugstore.com’s insurance carriers should arise, drugstore.com’s maximum financial obligation to plaintiffs pursuant to the settlement agreement would be less than $3.4 million.

On February 15, 2005, the Court granted preliminary approval of the settlement agreement, subject to certain modifications consistent with its opinion. These modifications have been made. There is no assurance that the Court will grant final approval to the settlement. We are unable to estimate the potential damages that might be awarded if the settlement were not approved, we were found liable, there arose a material limitation with respect to our insurance coverage, or the amount awarded were to exceed our insurance coverage. Because our liability, if any, cannot be reasonably estimated, no amounts have been accrued for this matter. An adverse outcome in this matter could have a material adverse affect on our financial position and results of operations.

State Sales Tax Claims. In early 2002, we received an arbitrary assessment notice from the state of New Jersey for past sales tax due from fiscal years 2000 and 2001, based upon its best estimate of sales revenue numbers during those periods. In December 2002, we received a revised assessment from the state of New Jersey for 2000 and 2001 in the amount of $221,626 in tax, plus penalties in the amount of $11,081 and interest that continues to accrue. We do not currently collect and do not believe that we are required to collect New Jersey sales tax. In March 2003, we filed an appeal of the revised assessment with the Tax Court of New Jersey, based on the fact that the state of New Jersey is pursuing its claim specifically against one of our consolidated subsidiaries that is not the retailing entity in that state. The appeal is pending and trial is scheduled for March 2006. Due to the uncertainty of the appeal, no amounts have been recorded in the accompanying financial statements with respect to the sales tax alleged to be due. If we are unsuccessful in our appeal, the state of New Jersey may expand its assessment to include other years for which we did not collect sales tax. No amounts have been accrued for this matter as our liability, if any, cannot be reasonably estimated. However, the ultimate outcome of this matter could result in substantial tax liabilities for our past sales and have a material adverse affect on our financial position and results of operations.

Federal Securities Action . On and after June 25, 2004, several putative class actions were filed in the United States District Court for the Western District of Washington against drugstore.com and certain of its present and former officers for alleged violations of the federal securities laws. The suits purport to have been filed on behalf of purchasers of our common stock between January 14, 2004 and June 10, 2004. The complaints generally allege that the defendants made false and misleading statements about our prospects for fiscal year 2004 and failed to disclose, among other things, (i) a negative impact on our gross margins from the integration of our acquisition of Vision Direct and from our free 3-day shipping promotion, and (ii) a negative impact on our sales growth arising from cancellations of certain expired prescriptions. On October 8, 2004, the Court issued an order consolidating the individual actions. On November 1, 2004, the Court appointed lead plaintiffs and lead plaintiffs’ counsel. On January 11, 2005, the

9

Table of Contents

Consolidated Amended Complaint was filed by the lead plaintiffs. On March 15, 2005, the defendants moved to dismiss the complaint, and October 19, 2005, the Court granted the motion and dismissed all of the plaintiffs’ claims. Applying the heightened pleading standards of the Private Securities Litigation Reform Act of 1995, or PSLRA, the Court found that all of the allegedly false statements were “forward-looking statements” and were accompanied by sufficient cautionary language to fall under the safe harbor for forward-looking statements provided by the PSLRA. Plaintiffs were granted 30 days to amend the complaint, and we do not know whether they will do so. No amounts have been accrued for this matter, as our liability, if any, cannot be reasonably estimated. The ultimate outcome of this matter could have a material adverse effect on our financial position and results of operations.

Stockholder Derivative Action . On August 13, 2004, two stockholder derivative actions were filed by plaintiffs Gerald Rusk and George Zimmer in the Superior Court of the state of Washington, King County, against certain of our present and former officers and directors. The derivative plaintiffs allege breach of fiduciary duty based on the failure to prevent the disclosure violations alleged in the securities complaints. Plaintiffs also allege abuse of control, gross mismanagement, waste of corporate assets, and unjust enrichment. These actions seek damages from the defendants on behalf of drugstore.com, which is a nominal defendant in the actions. Plaintiffs allege that certain of the defendants breached their fiduciary duties by selling drugstore.com stock while in possession of material non-public information. On January 21, 2005, the defendants moved to stay proceedings pending further developments in the federal securities action. On June 13, 2005, the Court denied the motion to stay. Plaintiffs filed a consolidated amended complaint on July 29, 2005 and, by stipulation of the parties, the defendants must respond by November 15, 2005.

Although the stockholder derivative complaints do not seek financial relief directly from drugstore.com, the litigation could have financial consequences for us through, for example, the attorneys’ fees we incur and advances to the defendants and, if appropriate under the circumstances, indemnification of the defendants. No amounts have been accrued for this matter, as our liability, if any, cannot be reasonably estimated. An adverse outcome in this matter could have a material adverse effect on our financial position and results of operations.

Other. From time to time, we are subject to other legal proceedings and claims in the ordinary course of business. We are not currently aware of any such legal proceedings or claims that we believe will have, individually or in the aggregate, a material adverse effect on our business prospects, financial condition or operating results.

We have four reporting segments: over-the-counter (OTC), mail-order pharmacy, local pick-up pharmacy, and vision. The OTC segment is comprised of the sales and related costs of selling health, beauty, personal care, and wellness products through our websites and customized nutritional supplement programs through CNS. The OTC segment also includes wholesale OTC net sales and fulfillment fees generated through our agreement with Amazon.com, Inc., which we terminated effective November 9, 2005, and net sales of consignment products. The mail-order pharmacy segment is comprised of sales and the related costs of selling pharmaceuticals through the drugstore.com website for mail-order delivery. The local pick-up pharmacy segment is comprised of sales and the related costs of selling pharmaceuticals through the drugstore.com website and the RiteAid.com website for pick-up at a local Rite Aid store. Our vision segment reflects sales and related costs of selling contact lenses through Vision Direct. We manage our business segments based on contribution margin results. We define contribution margin as net sales attributable to a segment, less the direct cost of these sales and the incremental (variable) costs of fulfilling, processing and delivering the order (labor, packaging supplies, credit card fees, and royalty costs that are variable based on sales volume). In 2004, we revised our contribution margin definition and calculation methodology to reflect the benefits of segment advertising revenues and the impacts of royalty costs. Amounts previously reported have been reclassified to reflect these changes.

10

Table of Contents

The information presented below for these segments is information used by our chief operating decision maker in evaluating operating performance.

11

Table of Contents

Pursuant to her offer letter dated September 21, 2004, Dawn Lepore, our president, chief executive officer and chairman of the board, is entitled to receive a guaranteed bonus equal to 100% of her annual salary paid with respect to the 12-month period following October 11, 2004, the date on which she commenced her employment with us. On October 27, we announced that Ms. Lepore has elected to waive this guaranteed bonus.

Effective November 9, 2005, we terminated our wholesale OTC fulfillment agreement with Amazon.com, Inc. Neither party has any material obligations following termination. Wholesale OTC net sales under this agreement for the nine-month period ended October 2, 2005 were $5.8 million, or 2.0% of our total net sales and 4.5% of our total OTC net sales. Our net sales guidance provided in the “ Management Outlook ” discussion contained in Part I, Item 2 of this quarterly report reflects the termination of this agreement.

The following discussion and analysis should be read in conjunction with the financial statements and accompanying notes included elsewhere in this quarterly report and in our annual report on Form 10-K for the fiscal year ended January 2, 2005.

Special Note Regarding Forward-Looking Statements

This quarterly report on Form 10-Q includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding industry prospects and our future financial and operational performance, made in this quarterly report are forward-looking. Words such as “expects,” “believes,” “anticipates,” “targets,” “intends,” “may,” “will,” “plan,” “continue,” “forecast,” “remains,” “would,” “should,” and similar expressions, are intended to identify forward-looking statements. Forward-looking statements are based on current expectations, are not guarantees of future performance and involve assumptions, risks, and uncertainties. Our actual results may differ significantly from those stated or implied in the forward-looking statements for a variety of reasons, including, among others, effects of changes in the economy, consumer spending, fluctuations in the stock market, changes affecting the Internet, online retailing and advertising, the company’s limited operating history, difficulties establishing our brand, including the risk that our current brand campaign may not be as successful as we anticipate, difficulties in building a critical mass of customers, the unpredictability of future revenues and expenses and potential fluctuations in revenues and operating results, risks related to business combinations and strategic alliances, possible tax liabilities relating to the collection of sales tax, consumer trends, the level of competition, seasonality, the timing and success of expansion efforts, recent changes in senior management, risks related to systems interruptions, possible governmental regulation and the ability to manage a rapidly growing business. These and other risks and uncertainties that could cause our actual results to differ significantly from management’s expectations are described in the following discussion, in the section entitled “Business – Additional Factors That May Affect Our Business and Future Results ” in Part I, Item 1 of our annual report on Form 10-K for the fiscal year ended January 2, 2005, filed with the Securities and Exchange Commission, or SEC, on March 18, 2005. A forward-looking statement should not be relied upon as representing our views as of any date other than the date on which we made the statement. We expressly disclaim any intent or obligation to update any forward-looking statement after the date on which we make it, except as we otherwise specifically state.

Overview

drugstore.com, inc. is a leading online provider of health, beauty, wellness, vision and pharmacy products. We believe that we offer a better way for consumers to shop for these products through our web stores, including those located on the Internet at www.drugstore.com, www.beauty.com, www.visiondirect.com, www.lensmart.com and www.lensquest.com and available toll-free by telephone at 1-800-DRUGSTORE and 1-800-VISIONDIRECT. We operate primarily in the United States and Canada, but our products are available to consumers worldwide.

Business Segments; Growth Strategies . We operate our business in four primary business segments: over-the-counter, or OTC, mail-order pharmacy, local pick-up pharmacy, and vision. The organization of our business into these four distinct segments allows our management to gain a comprehensive financial view of each of our key businesses and our business as a whole. In addition, this segmentation better allows us to align strategies in operations, marketing and customer care in order to optimize the overall customer experience, both within each segment and across all segments, and to maximize growth.

12

Table of Contents

Revenue . We generate revenue primarily from product sales and shipping fees. For the third quarter of 2005, we reported consolidated total net sales of $96.6 million, which reflects a $12.3 million, or 15%, increase over the third quarter of 2004. This net sales growth was driven primarily by a 14% year-over-year increase in order volume, to 1.3 million orders. Our average net sales per order remained at $77. Our net sales benefited from strong year-over-year growth in our flagship OTC and mail-order pharmacy segments, which grew by 18% and 19%, respectively, in the third quarter of 2005. (Excluding wholesale OTC net sales of $1.5 million in the third quarter of 2005, compared to $3.6 million in the third quarter of 2004, our net sales in the OTC segment increased by 27% year-over-year.) Net sales in our vision and local pick-up segments increased by 14% and 6%, respectively, year-over-year.

Expenses . Our operating expenses, including cost of goods sold, decreased in the third quarter of 2005 to 108% of net sales, compared to 139% in the third quarter of 2004, primarily due to the absence of impairment charges of $26.5 million recorded to goodwill and other intangible assets in the third quarter of 2004 related to our vision segment. In addition, our fixed corporate infrastructure costs were spread over greater net sales. In the third quarter, fulfillment and order processing costs and general and administrative costs both decreased year-over-year as a percentage of net sales, while technology and content costs and marketing and sales costs increased year-over-year as a percentage of net sales. Cost of goods sold declined slightly year-over-year.

Net Loss; Cash Position . Our net loss for the third quarter decreased by 78%, or $25.7 million, to $7.1 million, compared to $32.8 million for the third quarter of 2004, primarily as a result of the $26.5 million impairment charge in the third quarter of 2004. We ended the third quarter with $46.2 million in cash, cash equivalents and marketable securities, compared to $34.2 million at January 2, 2005. This balance reflects cash flow activity in the first nine months of 2005 consisting of $26.0 million in proceeds from the sale of 10.0 million shares of our common stock in a private placement, $1.0 million in proceeds from an advance under our revolving line of credit, and $2.0 million in proceeds from the exercise of stock options and sales under our employee stock purchase plan, partially offset by the use of $10.6 million to fund operating activities, $1.2 million to repay long-term debt obligations and $5.2 million for capital expenditures.

Significant Accounting Judgments

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires estimates and assumptions that affect the reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities in the consolidated financial statements and accompanying notes. The SEC has defined a company’s critical accounting policies as the ones that are most important to the portrayal of the company’s financial condition and results of operations, and that require the company to make its most difficult and subjective judgments, often as a result

13

Table of Contents

of the need to make estimates of matters that are inherently uncertain. Based on this definition, we have identified the significant accounting policies and judgments addressed below. We also have other key accounting policies that involve the use of estimates, judgments and assumptions that are significant to understanding our results. Additional information about our significant accounting policies is included in Note 3 of our condensed consolidated financial statements included in Part I of this quarterly report. Although we believe that our estimates, assumptions and judgments are reasonable, they are based upon information presently available. Actual results may differ significantly from these estimates under different assumptions, judgments or conditions. In addition, any significant unanticipated changes in any of our assumptions could have a material adverse effect on our business, financial condition and results of operations.

Revenue Recognition

We recognize revenues in accordance with SEC Staff Accounting Bulletin, or SAB, No. 104, Revenue Recognition.

Revenues from sales of OTC, mail-order pharmacy and vision products delivered to customers (net of promotional discounts, cancellations, rebates and returns allowances) are recognized when the product is shipped and title passes to the customer. Return allowances, which reduce product sales, are estimated using historical experience. If our estimate of return allowances is too high, our revenues will be understated; if our estimate of these allowances is too low, our revenues will be overstated. Historically, product returns, and differences between our estimates and actual returns, have not been significant.

Revenues from sales of OTC products ordered through the Amazon.com website and fulfilled by drugstore.com are recognized when we ship the products from our distribution center. According to the criteria outlined in Emerging Issues Task Force Issue No. 99-19, Reporting Revenue Gross as a Principal Versus Net as an Agent, or EITF 99-19, we record fulfillment fees and revenues generated by this Amazon.com agreement in our OTC segment on a gross basis, because we believe we act as a principal, based on the fact that we bear general inventory risk associated with these sales. Effective November 9, 2005, we terminated this agreement with Amazon.com.

Revenues from sales of prescription products ordered online or by telephone through the drugstore.com web store or the RiteAid.com web store (which is powered by the drugstore.com web store) for pick-up at a Rite Aid store, including co-payments received and collected on our behalf by Rite Aid, are recognized when the customer picks up the product. In these circumstances, we utilize Rite Aid as our fulfillment partner. According to the criteria outlined in EITF 99-19, we record revenues in our local pick-up pharmacy segment on a gross basis, because we believe we act as a principal, based on the fact that, among other things, we bear both inventory risk and credit and collection risk associated with these sales.

For insured prescriptions in both our local pick-up and mail-order segments, the co-payment and the insurance reimbursement (which together make up the amount due to drugstore.com) constitute the full value of the prescription drug sale, and we receive this entire amount as cash. We therefore recognize the entire amount as revenue when the order is shipped to the customer (for mail order prescriptions) or picked up by the customer (for local pick-up prescriptions).

Periodically, we provide incentive offers to our customers to encourage purchases. Such offers include discounts on specific current purchases, or future rebates based upon a percentage of the current purchase, as well as other offers. Discounts, when accepted by our customers, are treated as a reduction to the sales price of the related transaction and are presented as a net amount in net sales. Rebates are treated as a reduction to sales price based on estimated redemption rates. Redemption rates are estimated using our historical experience for similar offers. Historically, our redemption rates have not differed materially from our estimates, which are adjusted quarterly.

Inventories

We value our inventories at the lower of cost (using the weighted-average cost method) or the current estimated market value. We regularly review inventory quantities on hand and adjust our inventories for shrinkage and slow-moving, damaged and expired inventory, which is recorded as the difference between the cost of the inventory and the estimated market value based on management’s assumptions about future demand for the products we offer and market conditions. We use a variety of methods to reduce the quantity of slow-moving inventory, including reducing sales prices on our websites, negotiating returns to vendors, and liquidating inventory through third parties. If our estimates of future product demand or our assumptions about market conditions are inaccurate, we will understate or overstate the provision required for excess and obsolete inventory. Historically, inventories have not differed materially from our estimates.

Goodwill and Other Intangible Assets

In accordance with Statement of Financial Accounting Standards No. 142, Accounting for Goodwill and Other Intangibles , or FAS 142, we do not amortize goodwill but instead test for impairment at least annually. We test for impairment at the beginning of the

14

Table of Contents

fourth quarter or whenever indicators of impairment occur. The first phase of the test screens for impairment. If impairment is determined, the second phase measures the impairment by comparing the fair value of the applicable reporting unit to its carrying value. Fair value is determined using either a discounted cash flow methodology or methodology based on comparable market prices.

We review our indefinite-lived intangible assets, other than goodwill, for impairment when indicators of impairment occur and annually at the beginning of the fourth quarter. We compare the carrying value of the asset to its estimated fair value and record an impairment charge when the carrying value of the asset exceeds the estimated fair value.

In accordance with Statement of Financial Accounting Standards No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets , or FAS 144, we review the carrying values of our amortized long-lived assets, including definite-lived intangible assets, whenever an indicator of impairment occurs. When facts and circumstances indicate that the carrying values of long-lived assets may be impaired, we perform an evaluation of recoverability. The determination of whether impairment exists is based on any excess of the carrying value over the expected future cash flows, as estimated through undiscounted cash flows, excluding interest charges. We measure any resulting impairment charge based on the difference between the carrying value of the asset and its fair value, as estimated through expected future discounted cash flows, discounted at a rate of return for an alternate investment.

If our estimates of revenue growth or future cash flows prove to be inaccurate, we may have a future impairment of goodwill or other intangible assets.

Legal Proceedings

We are currently involved in various claims and legal proceedings. Periodically, we review the status of each significant matter and assess our potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, we accrue a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based only on the best information available at the time. As additional information becomes available, we reassess the potential liability related to our pending claims and legal proceedings and may revise our estimates. Any such revisions in the estimates of the potential liabilities could have a material impact on our future results of operations and financial position. See Note 7 of our condensed consolidated financial statements, Commitments and Contingencies , included in this quarterly report, for a description of our material legal proceedings.

Results of Operations

Net Sales

Net sales includes gross revenues from sales of product and related shipping fees, net of discounts and provision for sales returns, third-party reimbursement and other allowances. Net sales also includes fulfillment fees and product revenue from our recently terminated wholesale OTC fulfillment agreement with Amazon.com, and consignment services fees earned from our arrangement with General Nutrition Companies, Inc., or GNC, under which we do not take title to the inventory and cannot establish pricing. Consignment service fees are booked on a net basis and constitute approximately 1% of total net sales in each period presented. Orders are billed to the customer’s credit card or, in the case of prescriptions covered by insurance, the co-payment is billed to the customer’s credit card and the remainder of the prescription price is billed to insurance. Sales of pharmaceutical products covered by insurance are recorded as the sum of the amounts received from the customer and the third party. Sales made to

15

Table of Contents

Amazon.com under our wholesale OTC fulfillment agreement were billed directly to Amazon.com and recorded at the gross amount received from Amazon.com.

Total net sales increased for the three- and nine-month periods ended October 2, 2005, compared to the three- and nine-month periods ended September 26, 2004, primarily as a result of a 14% increase in order volume in the three-month period ended October 2, 2005, to 1.3 million orders, and a 12% increase in order volume in the nine-month period ended October 2, 2005, to 3.8 million orders. This increase in order volume resulted primarily from strong growth in our OTC and mail-order pharmacy segments. The number of customer orders includes new and repeat orders made through the drugstore.com website and the websites of our subsidiaries, and orders generated through our wholesale OTC fulfillment agreement with Amazon.com. Total net sales also benefited from an increase of 2% in the average net sales per order in the nine-month period ended October 2, 2005, to $77 compared to $76, and remained flat at $77 in the three-month period ended October 2, 2005 compared to the same period in 2004.

Our net sales in the OTC segment (including wholesale OTC) increased year-over-year by 18%, to $41.7 million, and by 20%, to $129.3 million, for the three- and nine-month periods ended October 2, 2005. For the three- and nine-month periods ended September 26, 2004, net sales in this segment were $35.2 million and $107.4 million. Excluding wholesale OTC net sales and fulfillment fees of $1.5 million and $5.8 million for the three- and nine-month periods ended October 2, 2005, our net sales in the OTC segment increased year-over-year by 27% and 26%. For the three- and nine-month periods ended September 26, 2004, wholesale OTC net sales and fulfillment fees were $3.6 million and $9.5 million. The increase in OTC net sales reflects increases of 20% and 19% in the number of OTC orders for the three- and nine-month periods ended October 2, 2005, to 764,000 orders and 2.3 million orders, compared to 635,000 orders and 1.9 million orders for the three- and nine-month periods ended September 26, 2004. Of the total number of orders, 68,000 and 218,000 orders were wholesale OTC orders in the three- and nine-month periods ended October 2, 2005, compared to 89,000 and 242,000 wholesale OTC orders in the three- and nine-month periods ended September 26, 2004. The increase in OTC net sales also reflects a slight year-over-year increase in the average net sales per order for the nine-month period ended October 2, 2005, which resulted from increases in the average number of items per order and revenue per item. Average net sales per order decreased slightly year-over-year for the three-month period ended October 2, 2005, as a result of a decrease in the revenue per item shipped resulting from our ongoing pricing strategies and promotional activities, partially offset by an increase in the average number of items per order.

Our net sales in the mail-order pharmacy segment increased year-over-year by 19%, to a historical quarterly high of $19.2 million, and by 21%, to $55.6 million, for the three- and nine-month periods ended October 2, 2005. For the three- and nine-month periods ended September 26, 2004, net sales in this segment were $16.2 million and $45.8 million. The increase in net sales reflects increases of 11% and 12% in the number of mail-order pharmacy orders for the three- and nine-month periods ended October 2, 2005, to 129,000 orders and 383,000 orders, compared to 116,000 orders and 342,000 orders for the three- and nine-month periods ended September 26, 2004. The increase in mail-order pharmacy net sales also reflects a year-over-year increase in each period in average net sales per order. The increase in average net sales per order resulted from a larger proportion of customers purchasing supply quantities of 90 days or more and a year-over-year increase of 6% in prescription prices resulting from higher pharmaceutical costs.

Our net sales in the local pick-up pharmacy segment increased year-over-year by 6%, to $23.4 million, and by 8%, to $72.3 million, for the three- and nine-month periods ended October 2, 2005. For the three- and nine-month periods ended September 26, 2004, net sales in this segment were $22.1 million and $66.7 million. The increase in net sales in the three-month period ended October 2, 2005 resulted from an increase in average net sales per order resulting from increases in the average price per prescription charged by Rite Aid and the average number of prescriptions per order. Local pick-up pharmacy orders for the three-month period ended October 2, 2005 decreased slightly to 210,000 orders, compared to 213,000 orders for the three-month period ended September 26, 2004. The increase in local pick-up pharmacy net sales in the nine-month period ended October 2, 2005 reflects a year-over-year increase of 3% in the number of local pick-up pharmacy orders for the nine-month period ended October 2, 2005, to 668,000 orders, compared to 652,000 orders for the nine-month period ended September 26, 2004. The increase in net sales in the nine-month period ended October 2, 2005 also resulted from increases in average net sales per order resulting from increases in the average price per prescription charged by Rite Aid and the average number of prescriptions per order.

Our net sales in the vision segment increased year-over-year by 14%, to $12.3 million, and decreased year-over-year by 2%, to $35.8 million, for the three- and nine-month periods ended October 2, 2005. For the three- and nine-month periods ended September 26, 2004, net sales in this segment were $10.8 million and $36.5 million. The increase in net sales for the three-month period ended October 2, 2005 reflects an increase of 9% in the number of vision orders, to 149,000 orders, compared to 136,000 orders for the three-month period ended September 26, 2004, and a year-over-year increase in the average net sales per order. The decrease in vision net sales for the nine-month period ended October 2, 2005 reflects a decrease of 7% in the number of vision orders, to 435,000 orders, compared to 467,000 orders for the nine-month period ended September 26, 2004, partially offset by a year-over-year increase in average net sales per order. The year-over-year increases in average net sales per order resulted primarily from an increase in the average number of items per order and increased purchases of higher-priced specialty contact lenses.

16

Table of Contents

Customer Data. We obtained 286,000 new customers during the third quarter of 2005, increasing our total customer base to approximately 6.8 million customers since inception. Orders from repeat customers as a percentage of total orders increased to 72% and 71% for the three- and nine-month periods ended October 2, 2005, compared to 69% and 68% for the three- and nine-month periods ended September 26, 2004, reflecting a 9% increase in our trailing 12-month active customer base. Wholesale OTC orders are included in the number of total orders but are considered neither repeat nor new orders for purposes of calculating repeat orders as a percentage of total orders. Our trailing 12-month active customer base grew to 2.0 million customers as of the end of the third quarter of 2005, compared to 1.8 million customers as of the end of the third quarter of 2004. Our trailing 12-month net sales per active customer grew year-over-year by $17, or 10%, to approximately $193 as of the end of the third quarter of 2005. Our trailing 12-month active customer base, which reflects those customers who have purchased at least once within the last 12 months, and our trailing 12-month net sales per active customer exclude customers and revenue associated with our recently terminated wholesale OTC business.

Cost of Sales

Cost of sales consists primarily of the cost of products sold to our customers, including allowances for shrinkage and damaged, slow-moving and expired inventory, outbound and inbound shipping costs, and expenses related to promotional inventory included in shipments to customers. Payments that we receive from vendors in connection with volume purchase or rebate allowances are netted against cost of sales.

Total cost of sales increased in absolute dollars for the three- and nine-month periods ended October 2, 2005, compared to the three- and nine-month periods ended September 26, 2004, as a result of growth in order volume and net sales. Cost of sales as a percentage of net sales decreased slightly year-over-year for the three-month period ended October 2, 2005 primarily as a result of higher product margins in our OTC segment, partially offset by higher shipping costs. Cost of sales as a percentage of net sales increased slightly year-over-year for the nine-month period ended October 2, 2005 primarily as a result of higher shipping costs, partially offset by higher product margins in our OTC segment.

Cost of sales in our OTC segment increased to $30.5 million and $94.0 million for the three- and nine month periods ended October 2, 2005, compared to $26.0 million and $77.8 million for the three- and nine-month periods ended September 26, 2004, primarily as a result of increased order volume. Cost of sales as a percentage of net sales in this segment decreased year-over-year for the three-month period ended October 2, 2005 as a result of increased product margins, partially offset by higher per-order shipping costs. Cost of sales as a percentage of net sales increased slightly for the nine-month period ended October 2, 2005 as a result of higher per-order shipping costs, partially offset by increased product margins. Per-order shipping costs increased in both periods for the reasons discussed below.

Cost of sales in our mail-order pharmacy segment increased to $16.6 million and $48.1 million for the three- and nine-month periods ended October 2, 2005, compared to $13.9 million and $39.0 million for the three- and nine-month periods ended September 26, 2004, as a result of increased order volume and higher per-order product costs. Per-order product costs, and cost of sales as a percentage of net sales, in this segment increased year-over-year for the three- and nine-month periods ended October 2, 2005, as a result of our initiatives to grow this segment by providing third-party fulfillment services to PBMs. This strategy focuses on fulfilling 90-day-or-greater order quantities, which generates higher per-order revenue than 30-day quantity orders but also results in higher per-order product costs and lower product margins.

Cost of sales in our local pick-up pharmacy segment increased to $20.5 million and $63.7 million for the three- and nine-month periods ended October 2, 2005, compared to $19.7 million and $59.8 million for the three- and nine-month periods ended September 26, 2004, as a result of increased product costs in both periods and increased order volume in the nine-month period ended October 2,

17

Table of Contents

2005. Cost of sales as a percentage of net sales in this segment decreased year-over-year in the three- and nine-month periods ended October 2, 2005 as a result of selling a higher proportion of higher-margin generic drugs compared to lower-margin branded drugs, as well as higher product margins on sales of generic drugs.

Cost of sales in our vision segment increased to $9.8 million and $28.0 million for the three- and nine-month periods ended October 2, 2005, compared to $8.1 million and $27.6 million for the three- and nine-month periods ended September 26, 2004, as a result of increased shipping costs for both periods and increased order volume and higher per-order product costs for the three-month period ended October 2, 2005. Cost of sales as a percentage of net sales in this segment increased year-over-year in the three-month period ended October 2, 2005 as a result of higher per-order product costs, increased promotional activity, and higher shipping costs. Cost of sales as a percentage of net sales increased year-over-year in the nine-month period ended October 2, 2005 as a result of higher shipping costs and increased promotional activity. The increase in shipping costs in both periods reflected a rate increase from one of our shipping carriers.

Shipping costs, which are included in cost of sales, continue to exceed the amount we charge customers for shipping. During the last week of the first quarter of 2005, we discontinued our shipping policy that provided free 3-day shipping on non-prescription orders of $49 or more. We replaced this shipping policy with a tiered policy, under which our standard ground shipping fee has increased to $5.99 from $5.49 (or free with non-prescription orders of $49 or more) and 3-day shipping is provided for a fee of $8.95 (or free with non-prescription orders of $99 or more). The cost reductions resulting from this change in our shipping policy were neutralized by rate increases and fuel surcharges from our shipping carriers, a higher proportion of orders being shipped to Alaska, Hawaii, U.S. Territories, and APO/FPO (which are more expensive to ship), and greater package weights resulting from a greater number of items per order. Beginning in November 2005, shipping surcharges will apply to shipments to Alaska, Hawaii, U.S. Territories, and APO/FPO, and we will increase the upgrade charge for 3-day shipping for customers who qualify for free ground shipping (those with non-prescription orders of $49 or more) from $3 to $3.99.

Fulfillment and Order Processing Expenses